The oncolytic effects of herpes simplex virus-1 (HSV-1) are limited, possibly because of premature death of infected cells by apoptosis, which limits the amount of progeny virus that is produced. It has been proposed that inhibition of apoptosis in infected tumor cells would allow increased viral persistence, replication and therapeutic effect. To test this hypothesis, we infected monocyte chemoattractant factor-7 (MCF-7) and MDA-MB-231 breast cancer cells with HSV-1 strain 17 þ and 17Dg34.5 in the presence or absence of N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVADfmk), a pan-caspase inhibitor. At low doses of HSV-1 strain 17 þ and 17Dg34.5, the growth of MCF-7 cells was reduced to 37% or 42%, respectively, of uninfected cells.
Introduction
Many different viruses have been engineered for oncolytic virotherapy. These viruses are designed to target specific tumor cell types, tumor environments, cells with dysregulated proteins and may contain additional genes that stimulate the immune response. Herpes simplex virus-1 (HSV-1) is a suitable candidate virus because of its large genome with many non-essential proteins, ease of manipulation, natural oncolytic properties and wide host tropism. [1] [2] [3] The removal of virulence genes enhances the safety of HSV-1 vectors against serious complications and/or reversion to wild type. [4] [5] [6] Some of these oncolytic HSV-1 viruses have been approved for clinical trials in breast cancer, 3, 7 head and neck carcinoma, 8 glioma, 9 melanoma, 10 non-small-cell lung carcinoma 11 and metastases from colorectal cancer 12 (reviewed in Manservigi et al. 13 )
. These clinical trials demonstrate that HSV-1 vectors are generally well tolerated at high doses with few side effects. A phase III clinical trial is underway for the oncolytic HSV-1 mutant which expresses granulocyte and monocyte colony-stimulating factor, for the treatment of advanced melanoma. 10 Given the likely effectiveness of HSV-1 for cancer therapy, it is now important to optimize its effects. This has been attempted through the use of combination with other agents, such as chemotherapy, radiotherapy and/or adjuvant therapeutic genes. The second-generation HSV-1 mutant G207 has been combined with cisplatin for head and neck cancer, 8, 14 vincristine to treat rhabdomyosarcoma 15 and paclitaxel to combat anaplastic thyroid cancer. 16 All of these combination therapies were more effective than HSV-1 treatment alone. In addition, Dai et al. 17 demonstrated that HSV-1 combined with radiotherapy was more effective at inhibiting the growth of colorectal cancer cell lines and liver metastases. Finally, a recent phase I clinical trial with oncolytic HSV-1 virus, JS1/34.5-/47-/(granulocyte-macrophage-colony-stimulating factor), in combination with cisplatin-based chemotherapy demonstrated an optimal tolerated dose of HSV-1, and improved rates in relapse-free survival in squamous cell cancer of the head and neck. 14 Although these combinatory studies are all promising, they do not address a major weakness of HSV-1, which is its limited capability to replicate within a tumor. Indeed, although the main appeal of oncolytic herpes viruses is their potential for exponential increases in titer with passing time, in quantitative studies we have documented their gradual loss from animal tumors. 18 One reason for the loss of HSV-1 from tumors might be the rapid death of infected cells by apoptosis, which would limit the ability of the virus to replicate. HSV-1 expresses both pro-apoptosis and anti-apoptosis genes, and the balance between their effects determines the rate of death of the infected cells. HSV-1 infection triggers apoptosis by both caspase-dependent and -independent pathways, 19 but the expression of viral proteins 3-6 h post-infection (hpi) blocks cellular death and allows for efficient viral replication.
19-23 HSV-1 expresses multiple proteins that act to prevent cellular apoptosis including infected cell protein 4 (ICP4), ICP27, ICP34.5, U S 3 and U s 5 kinase, and gJ. 21, 22, 24, 25 Others have therefore proposed that anti-apoptosis drugs might allow infected tumor cells to resist apoptosis, at least temporarily, thus allowing greater replication of the virus and a stronger anti-tumor effect in the long term. 26 Apoptosis is a complex process, offering many target sites at which it could be inhibited. These include the various caspases, and it has previously been demonstrated that the pan-caspase inhibitor N-benzyloxycarbonylVal-Ala-Asp-fluoromethylketone (zVADfmk) can prevent HSV-1-induced apoptosis. 19 In this study, we tested if this caspase inhibitor can increase the persistence and replication of HSV-1 in breast cancer cells, thereby increasing its therapeutic potential.
Materials and methods

Cells
The human breast cancer cell lines, monocyte chemoattractant factor-7 (MCF-7) and MDA-MB-231, were kindly provided by Dr Y Wang (SUNY Upstate Medical University, Syracuse, NY) and Dr S Taffet (SUNY Upstate Medical University), respectively. Vero cells were obtained from the American Type Culture Collection (Rockville, MD). Cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U ml À1 of penicillin and streptomycin at 37 1C under 5% CO 2 . Pilot studies were performed for all experiments to establish suitable times and concentrations of reagents (data not shown).
Viruses
The HSV-1 17Dg34.5 mutant and its parental strain 17 þ syn were a kind gift from RS Coffin (Biovex Ltd, London, UK). Strain 17Dg34.5 has both copies of the g34.5 gene replaced with green fluorescent protein (GFP) under the control of a cytomegalovirus promoter. 5 Vero cells were used for virus propagation and to determine viral titer by a standard plaque assay. All infections were carried out in serum-free Dulbecco's modified Eagle's medium and allowed 1 h for viral absorption. Viruses were always used at the minimum concentration possible.
Apoptosis
The Cell Death Detection ELISA PLUS kit (Roche, Basel, Switzerland) was used following the manufacturer's instructions. 27 Cells were plated in a 96-well plate at 1. In some experiments, the culture medium was collected and pooled from replicate wells 5 days post-infection (dpi), diluted 1:4 in fresh medium and used to treat naı¨ve cells. The passage of medium was repeated sequentially up to five times, and zVADfmk was replenished at every media transfer. Before the last (5th) media transfer, some media were incubated in the absence or presence of the HSV-1/HSV-2 monoclonal anti-gD antibody (LifeSpan Biosciences, Seattle, WA) with 10% guinea-pig serum (Innovative Research, Novi, MI) for 1 h to neutralize virus.
Viral replication
Cells were plated in a 24-well dish at 1 Â 10 6 cells per well. The following day, cells were infected with 100 ml of 10 4 PFU ml À1 HSV-1 for 1 h. Cells were washed twice with serum-free medium and then grown in 0.5 ml Dulbecco's modified Eagle's medium with 10% fetal bovine serum. Viral titers were measured at 48 and 96 hpi by a standard plaque assay on Vero cells. 1 To determine the number of virus genomes, quantitative polymerase chain reaction (qPCR) was used. Viral DNA was isolated from cell lysates or medium using the DirectPCR Lysis reagent (Viagen Biotech, Los Angeles, CA) combined with 1 mg ml À1 proteinase K (Viagen) following the manufacturers' instructions. For analysis of media transfer experiments, DNA was isolated from 200 ml of pooled cell-associated media. PCR was performed with the iQ SYBR Green Supermix (BioRad, Hercules, CA). Oligonucleotide primers were DBP-3261 (5 0 -GGTGCAGAAAGGTGTTGTTG-3 0 ) and DBP-3315, 31 which correspond to HSV-1 nucleotides 61 522-61 541 and 61 595-61 576, respectively. PCR conditions were one cycle for 15 min at 95 1C, and then 36 cycles of 94 1C for 15 s, 58 1C for 20 s and 72 1C for 20 s. 32 Each PCR run contained a series of pUL29-OriL DNA dilutions (1 Â 10 3 -1 Â 10 8 copies per 5 ml) and a negative control DNA.
Microscopy
Medium that was being transferred for the fifth time, from cultures that had been originally infected with 10 3 PFU ml À1 HSV-1 strain 17g34.5, was used to infect MCF-7 and MDA-MB231 cells for 5 days. Some media were pre-incubated with anti-gD antibody. Cells were visualized by either differential interference contrast microscopy or by fluorescent microscopy using an inverted Olympus IX31 microscope (Center Valley, PA) and images were captured using the PictureFrame software (Optronics, East Muskogee, OK).
Statistical analysis
All statistics were calculated using the GraphPad Prism v.5.0 (GraphPad Software, San Diego CA). A Student's unpaired two-tailed t-test was used to determine the level of significance.
Results
Growth inhibition of infected breast cancer cells by HSV-1
The growth of the MCF-7 and MDA-MB-231 cells was inhibited by infection with HSV-1 strains 17 þ and 17Dg34.5 ( Figure 1 ). Inhibition was dose-dependent in all cases. With each virus, Vero cells were the most susceptible to growth inhibition, followed by MCF-7 cells and then MDA-MB-231 cells. Replication of HSV-1 in the presence of zVADfmk At 48 hpi, strain17 þ showed slightly reduced levels of PFU and 2.3-3.8-fold reduction in viral genomes following zVADfmk treatment. By 96 hpi, the PFU and viral genomes of 17 þ were similar in untreated and zVADfmktreated cells. At 48 hpi, 17Dg34.5 showed no change in PFU, but a 1.2-3.2-fold increase in viral genomes following zVADfmk treatment. By 96 hpi, 17Dg34.5 showed a 5.5-fold increase in PFU following zVADfmk treatment. The effect of zVADfmk on the number of viral genomes for 17Dg34.5 at 96 hpi was mixed, with an 11.5-fold increase in MCF-7 cells and a 5.2-fold decrease in MDA-MB-231 cells (Table 1) . Overall therefore the addition of zVADfmk enhanced the amount of infectious virus produced. þ and from 42 to 33% when combined with 17Dg34.5. Furthermore, the addition of zVADfmk to virus-infected MDA-MB-231 cells led to a further reduction in cell growth from 77 to 46% when combined with 17 þ , and from 35 to 24% when combined with 17Dg34.5 ( Figure 3 ). This suggests that HSV-1 treatment combined with zVADfmk enhances growth inhibition in breast cancer cells better than virus alone. 
Effect of HSV-1 and zVADfmk on apoptosis
Inhibition of breast cancer cells by HSV-1 LW Wood and EJ Shillitoe
Persistence of HSV-1 through serial transfer of cell culture medium To model viral spread or persistence in the intratumoral environment, cells were infected with very low doses of HSV-1 17 þ or 17Dg34.5, medium was collected from cells 5 dpi, pooled, diluted 1:4 in fresh culture medium and used to treat naı¨ve cell cultures. The media transfer process was repeated for four consecutive transfers. Cells treated with HSV-1 strain 17 þ were originally infected with 10 2 PFU ml À1 and strain 17Dg34.5 was used at 10 3 PFU ml (data not shown). When media from cells that had been exposed to HSV-1 alone was passed to subsequent cultures, it did not cause any growth inhibition (Figure 4) . In contrast, cell growth was strongly inhibited when media from zVADfmk plus virus-infected cells were passed. Specifically, MCF-7 or MDA-MB-231 cell growth was completely inhibited by the first or second media transfer when HSV-1 strain 17 þ was combined with zVADfmk ( Figure 4a ). With strain 17Dg34.5, the presence of zVADfmk resulted in complete growth inhibition on the third media transfer (Figure 4b ). The transferred medium was then examined by qPCR to quantify viral genomes ( Table 2 ). The addition of zVADfmk to HSV-1 strain 17 þ increased the number of detectable viral genomes in both MCF-7 and MDA-MB-231 cells after the second media transfer, at The collection and transfer of cell-associated medium was repeated four consecutive times. Growth of breast cancer cells was measured by an MTT assay for 7 days following transfer and expressed as a percentage of mock-infected cells with or without zVADfmk. Graphs are from a representative experiment; the same effect was seen in four separate experiments. Data points are the mean±s.e. of three replicate wells, **Po0.01.
which time complete growth inhibition was evident (Table 2) . A similar number of 17Dg34.5 viral genomes were detected in the absence and presence of zVADfmk in both cell lines after the second media transfer even though cell growth was inhibited only in the combination treatment group.
To find if the presence of zVADfmk in transferred medium had allowed increased persistence or replication of HSV-1 in infected cells, cells that were infected with strain 17Dg34.5 were examined by fluorescent microscopy ( Figure 5 ). Images were taken of cells 5 dpi of the fifth media transfer of cell-associated medium, where cells were originally infected with 10 3 PFU ml À1 HSV-1 strain 17Dg34.5. There were no green-fluorescing cells in the mock-infected controls (Figure 5b ). Cells infected with the virus alone had a small number of isolated GFP þ cells (Figures 5c and d) . In contrast, cells treated with cell-associated medium in combination with zVADfmk had numerous clusters of GFP-expressing cells (Figures  5e and f) . Similar results were obtained with MDA-MB-231 cells (not shown).
To determine if HSV-1 was solely responsible for the complete growth inhibition seen in the media transfer experiment, a subsequent media transfer was performed in which an anti-gD antibody with complement was used to neutralize HSV-1. To test the potency of the commercial anti-gD antibody, MCF-7 and MDA-MB-231 cells were infected with 10 4 PFU ml À1 HSV-1 strain 17 þ in the presence or absence of the antibody. This showed that anti-gD with complement restored growth to both MCF-7 and MDA-MB-231 HSV-1-infected cells (Figure 6 ). The same was observed with HSV-1 strain 17Dg34.5 (data not shown). When culture medium from HSV-1 þ zVADfmk-infected cells was incubated with anti-gD, the number of GFP-expressing cells was reduced to levels seen following mock infection (Figures 5g and h) . Similar results were observed in MDA-MB-231 cells (not shown).
Discussion
Previous research has demonstrated that HSV-1 has natural oncolytic properties, and preferentially infects cells that are actively dividing. 15 However, different cancer cell lines have different levels of susceptibility to the virus, 20 and therefore it is important to optimize its effects. We used cells from human breast carcinomas to test the hypothesis that combining HSV-1 infection with a caspase inhibitor would result in increased killing of cancer cells. MCF-7 and MDA-MB-231 breast cancer cells were chosen to represent estrogen-receptor-positive or -negative tumors, respectively. Expression of the estrogen receptor has been linked with chemotherapy resistance, 33 and thus the increased potency of anti-tumor treatment is necessary for these tumors. Both cell lines are well characterized and frequently used for breast cancer research. 34 The viruses that we tested were the laboratory strain 17 þ and a mutant derived from it by deletion of the g34.5 gene. The deletion of g34.5 from HSV-1 is a safety precaution because its expression is necessary for establishing infection within neurons. 31 Therefore, removal of this gene reduces the potential neurological complications associated with HSV-1 infection. However, as g34.5 has anti-apoptotic properties, 31, 35 the loss of this gene might affect the level of apoptosis in infected cells. Consistent with previous studies, 3, 6 the 17Dg34.5 viral mutant was still capable of inhibiting the growth of each of the cell types that were tested. This might have happened because human GADD34, a DNA repair protein, is homologous to part of the HSV-1 g34.5 and GADD34 upregulation allows some replication of g34.5-null viruses. 31 Although both of the cancer cell lines were susceptible to growth inhibition by HSV-1, they were less susceptible than the Vero cell line. MDA-MB-231 cells were more resistant to the virus than MCF-7 cells (Figure 1 ), and these results are in accordance with previous findings. 7 Although cell growth was inhibited by both strains of viruses, the mutant virus was, as expected, slightly less effective ( Figure 1 ). It is clear that HSV-1 inhibits the growth of breast cancer cells in vitro, but that the inhibition, especially with a mutant virus, is not optimal. These results support the view that the oncolytic potency of HSV-1 can be improved.
To find the effects of the two virus strains on apoptosis in breast cancer cells, apoptosis was induced by CPT, a topoisomerase II inhibitor, and the level of apoptosis was assessed by an enzyme-linked immunosorbent assay that detected histone-associated DNA fragments. DNA fragmentation is a classical marker of irreversible cellular apoptosis, and lies downstream of all effector caspases. MCF-7 cells were found to be more sensitive to CPT, and apoptosis was induced with 14.5 mM CPT for 16 h, where MDA-MB-231 needed 100 mM CPT for 40 h. In MCF-7 cells both strains of virus reduced the levels of CPT-induced apoptosis (Figure 2a) . Even the mutant virus, lacking one of the anti-apoptotic proteins, was able to reduce the levels of CPT-induced apoptosis. This trend was less obvious in MDA-MB-231 cells, where HSV-1 had less effect (Figure 2a) . These results confirm that there are multiple anti-apoptotic properties of HSV-1 and these pathways are still effective without the gene g34.5.
The pan-caspase inhibitor, zVADfmk, was confirmed as being capable of inhibiting apoptosis in both MCF-7 and MDA-MB-231 cells (Figure 2b ). There was a stronger inhibition of apoptosis in MCF-7 cells than in MDA-MB-231 cells, which might be attributable to the lack of caspase-3 in MCF-7 cells 21, 22 or other differences in the apoptotic cascade. These results established zVADfmk as a potent inhibitor of apoptosis in breast cancer cells.
In accordance with the hypothesis is the notion that the longer an infected cell remains alive, the more time the virus has to replicate and assemble infectious progeny. Viral replication was therefore measured using two different techniques-a standard plaquing assay to measure the number of infectious virus particles recovered and qPCR that quantified the number of viral genomes present. Replication experiments were conducted for Inhibition of breast cancer cells by HSV-1 LW Wood and EJ Shillitoe 48 and 96 hpi. The addition of zVADfmk had no effect on replication of HSV-1 strain 17 þ in either MCF-7 or MDA-MB-231 cells (Table 1) . Possibly the wild-type virus is maximally efficient at replication and even the addition of anti-apoptotic agents cannot enhance replication. With HSV-1 strain 17Dg34.5 at 48 hpi, there was no difference in the levels of infectious virus or the number of viral genomes, but at 96 hpi both MCF-7 and MDA-MB-231 cells demonstrated an increase in virus recovered by plaque assay when combined with zVADfmk treatment (Table 1) . Although previous work has shown that deletion of ICP34.5 attenuates HSV-1 mutants, it appears that zVADfmk can compensate for the lack of this anti-apoptotic gene to increase infectious virus production. Taken together, it appears that zVADfmk allows the mutant virus additional time to replicate and to package and assemble infectious virions. zVADfmk has previously been shown to allow increased replication of HIV in T cells, 36 but to decrease the replication of a coxsackievirus in B cells. 36 Clearly the effects of zVADfmk on viruses are variable and must be determined for each individual type of infection.
After establishing that zVADfmk increases the amount of infectious HSV-1, we asked if this had any effect on the growth of breast cancer cells. Cellular proliferation was monitored over 7 days using an MTT assay. HSV-1 at a low concentration was capable of inhibiting the growth of both MCF-7 and MDA-MB-231 cells (Figure 3) . Growth of the breast cancer cells infected with the wild-type virus was further inhibited by the addition of zVADfmk (Figure 3 ). Both cell types also exhibited a reduction in cell survival when 17Dg34.5 infection was combined with zVADfmk. There was a slight reduction in growth seen with zVADfmk alone, which might be attributed to the less than 1% of residual dimethyl sulfoxide, which is the solvent for the agent. Although the mutant still lacked the potency of the wild-type virus, the enhanced oncolysis seen with zVADfmk could potentially serve to lower the amount of virus necessary for patient treatment. Collectively, it is clear that the addition of zVADfmk enhances the inhibitory effects of HSV-1 in breast cancer cells in vitro.
For an optimal oncolytic effect it is necessary that once virus replication occurs, the progeny should infect neighboring cells. To find if this is plausible, we designed a technique where culture medium from infected cells was transferred to naı¨ve cells, thereby modeling the spread of extracellular virus in a tumor. The medium from HSV-1-infected breast cancer cells, with either viral strain, had no effect on the growth of naı¨ve cells. However, the addition of zVADfmk resulted in complete growth inhibition of naı¨ve cells (Figure 4) . Transfer of medium from cells infected with HSV-1 strain 17 þ with zVADfmk abolished the growth of MCF-7 cells on the first media transfer. A similar trend was seen in MDA-MB-231 cells, although growth was not completely inhibited until the second passage of culture medium. The delay might be accounted for by the fact that MDA-MB-231 cells are more resistant to viral infection than MCF-7 cells. The 17Dg34.5 strain of virus was capable of preventing growth in both cell types on the third media transfer. As the mutant has been shown to be inferior to the wild-type virus, it is not surprising that it takes additional passages to prevent further cell growth. The addition of zVADfmk may allow for the use of low viral doses for patients; here the breast cancer cells were only infected with 10 3 PFU ml
À1
of HSV-1 strain 17Dg34.5. Following the transfers, parallel qPCR demonstrated large numbers of viral genomes before arrest of breast cancer cell growth ( Table 2 ). The number of viral genomes was increased by zVADfmk at most media transfer times.
To confirm that HSV-1 was indeed transferred by the culture media to the naı¨ve cultures, we took advantage of the fact that the mutant strain 17Dg34.5 strain expresses GFP, which can be seen by fluorescent microscopy. A fifth media transfer was conducted and mock-infected wells displayed no GFP þ cells. Cells originally infected with 17Dg34.5 contained some cells exhibiting cytopathic effect and were GFP.
þ When zVADfmk was combined with HSV-1 infection, there was a large increase in GFP þ MCF-7 cells ( Figure 5 ). Thus, zVADfmk had indeed permitted the persistence of HSV-1 in media that were transferred to subsequent cultures.
We considered it necessary to confirm that the growthinhibitory effect of the transferred media was indeed due to HSV-1, because the media must also have contained the remnants of necrotic, apoptotic and HSV-1-lysed cells, and would include cytokines, apoptotic bodies and cellular debris as well as virus. First, it was established that anti-gD was a neutralizing antibody that was complement-dependent ( Figure 5a , data not shown). When anti-gD was then incubated with media from HSV-1-infected zVADfmk-treated cells, very few GFP þ cells were visualized. The media from these cultures also failed to inhibit the growth of a naı¨ve culture (data not shown). These results confirm that it was HSV-1 that was the agent in the media that was responsible for the growth inhibition of the cells.
The use of zVADfmk in human clinical trials is quite feasible. Its mode of action is well defined. It has a tripeptide core that is a caspase recognition site, and is modified by fluoromethylketone to increase cellular permeability and to make the caspase-binding irreversible. 28 It also inhibits the lysosomal protease cathepsin D, 37 and the adenosine nucleotide translocator that is involved in autophagy or necrosis. 29 It appears that zVADfmk can be administered systemically to animals without significant side effects. In fact, beneficial effects have been reported in the treatment of apoptosisdependent conditions such as ischemic injury, 38 trauma 39 and loss of tissue transplants. 40, 41 Thus, it seems likely that systemic zVADfmk could be a valuable adjunct to the use of an oncolytic virus.
The use of herpes simplex virus as a therapeutic agent will only be possible if the risk of viral spread can be managed. This would be particularly important if the virus was combined with agents that increase its potency. Fortunately, there are several ways to manage such risks. Deletions of non-essential genes such as Dg34.5 can reduce neurovirulent behavior. Alternatively, essential genes of the virus can be placed under the control of tissue-specific promoters, thus limiting their replication to specific tissues. [1] [2] [3] Finally, therapeutic strains in which the virus thymidine kinase gene remains unmodified will still be susceptible to antiviral drugs such as acyclovir. The combination of modified viruses with chemical agents to increase their potency in tumors shows promise for use in the treatment of human cancers.
